News
'Keytruda is King' in lung cancer, putting BMS and next-gen ...
Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug could revolutionise treatment when combined with chemotherapy.
